公开(公告)号：US10532051B2

公开(公告)日：2020-01-14

申请号：US14875506

申请日：2015-10-05

申请人： ChemoCentryx, Inc.

发明人： Karen Ebsworth ,  Yu Wang ,  Yibin Zeng ,  Penglie Zhang ,  Joanne Tan

IPC分类号： A61K31/502 ,  A61K31/4412 ,  A61K31/4709 ,  A61K31/517 ,  A61K31/415 ,  A61K31/5377 ,  A61K39/395 ,  C07K16/28 ,  A61P1/00

摘要： Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-α4β7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-α4β7 integrin antibody.

公开(公告)号：US11708326B2

公开(公告)日：2023-07-25

申请号：US17106309

申请日：2020-11-30

申请人： CHEMOCENTRYX, INC.

发明人： Christopher Lange ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Yu Wang ,  Ju Yang ,  Penglie Zhang

IPC分类号： C07D207/12 ,  A61K45/06 ,  C07D401/12 ,  C07D207/267 ,  C07D211/44 ,  C07D403/12 ,  C07D211/38 ,  C07D451/06 ,  C07D205/12 ,  C07F5/02 ,  C07D405/14 ,  C07D401/14 ,  C07D471/10 ,  C07D211/76 ,  A61P37/02 ,  C07D205/04 ,  C07D213/85 ,  C07D295/088 ,  C07D487/10 ,  C07D405/12 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/40 ,  C07D211/46

CPC分类号： C07D207/12 ,  A61K31/40 ,  A61K31/445 ,  A61K31/4427 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  A61P37/02 ,  C07D205/04 ,  C07D205/12 ,  C07D207/267 ,  C07D211/38 ,  C07D211/40 ,  C07D211/44 ,  C07D211/46 ,  C07D211/76 ,  C07D213/85 ,  C07D295/088 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D451/06 ,  C07D471/10 ,  C07D487/10 ,  C07F5/025

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I):




including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US10919852B2

公开(公告)日：2021-02-16

申请号：US16047545

申请日：2018-07-27

申请人： CHEMOCENTRYX, INC.

发明人： Christopher Lange ,  Viengkham Malathong ,  Venkat Reddy Mali ,  Jeffrey McMahon ,  Darren J. McMurtrie ,  Sreenivas Punna ,  Howard S. Roth ,  Rajinder Singh ,  Yu Wang ,  Ju Yang ,  Penglie Zhang

IPC分类号： C07D401/12 ,  C07D401/10 ,  A61P37/02 ,  C07D207/12 ,  A61K45/06 ,  C07D207/267 ,  C07D211/44 ,  C07D403/12 ,  C07D211/38 ,  C07D451/06 ,  C07D205/12 ,  C07F5/02 ,  C07D405/14 ,  C07D401/14 ,  C07D471/10 ,  C07D211/76 ,  C07D205/04 ,  C07D213/85 ,  C07D295/088 ,  C07D487/10 ,  C07D405/12 ,  A61K31/40 ,  A61K31/4427 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4545 ,  C07D211/40 ,  C07D211/46

摘要： Compounds are provided that are useful as immunomodulators. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein Z, L, R1a, R1b, R1c, R1d, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.